This study tested the hypothesis that multivitamin supplementation given to HIV+ pregnant women in Tanzania would slow disease progression and enhance their overall health.
In this study, we sought to examine whether the administration of multivitamins excluding vitamin A, multivitamins including vitamin A, or vitamin A alone would reduce the risk of perinatal transmission of HIV and slow the rate of disease progression in a group of pregnant HIV infected women. We also examined the efficacy of the supplements on pregnancy outcomes, and risks of maternal and child morbidity and wasting.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
1,085
one daily oral dose of 30 mg beta-carotene + 5000 IU preformed vitamin A
one daily oral dose of 20 mg thiamine (vitamin B-1), 20 mg riboflavin (vitamin B-2), 25 mg vitamin B-6, 100 mg niacin, 50 ug cobalamin (vitamin B-12), 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid
Placebo pill
Harvard School of Public Health
Boston, Massachusetts, United States
To examine the effect of multivitamin and/or Vitamin A supplements on the risk of perinatal transmission of HIV and rate of HIV disease progression
Time frame: until the end of follow-up in August, 2003
To examine the effect of multivitamin and/or Vitamin A supplements on child and maternal morbidity, child growth and child mortality
Time frame: until the end of follow-up in August 2003
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.